IMUX — Immunic Income Statement
0.000.00%
Last trade - 00:00
- $109.90m
- $63.22m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 37 | 49 | 91.7 | 119 | 99.2 |
Operating Profit | -37 | -49 | -91.7 | -119 | -99.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -34.9 | -44 | -92.9 | -120 | -93.6 |
Net Income After Taxes | -34.9 | -44 | -92.9 | -120 | -93.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -34.9 | -44 | -92.9 | -120 | -93.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -34.9 | -44 | -92.9 | -120 | -93.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -4.52 | -2.81 | -3.2 | -2.75 | -2.11 |